A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax plus Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients=60 YearsUma M. Borate,Ying Huang, Mary F. Johnson,Joshua F. Zeidner,Ronan T. Swords,Kristin L. Koenig,Eytan M. Stein,Maria R. Baer,Wendy Stock,Yazan F. Madanat,Rebecca Olin,William Blum,Gary J. Schiller,Tara L. Lin,Robert L. Redner,Emily K. Curran,Nyla A. Heerema, Molly Martycz,Leonard Rosenberg,Sonja Gullen Marcus,Timothy Chen,Mona Stefanos,Ross L. Levine,Brian J. Druker,Ashley Owen Yocum,Amy Burd,Alice Mims,John C. ByrdBLOOD（2023）引用 0|浏览13暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
